Drug Trial Radar · NCT01225874
Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL
Last checked: Nov 20, 2026Latest source record: Feb 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,762
Actual
Start
Dec 1999
Primary completion
Mar 2006
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 21, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Studying samples of blood or bone marrow from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This trial is studying biomarkers to classify young patients with acute lymphoblastic leukemia (ALL) and remission induction therapy in young patients with B-precursor ALL.
Conditions
- Leukemia
Interventions
SC-PEG E. coli L-asparaginaseDrug
Given IM
cytarabineDrug
Given IT
daunorubicin hydrochlorideDrug
Given IV
dexamethasoneDrug
Given orally
methotrexateDrug
Given IT
pegaspargaseDrug
Given IM
prednisoneDrug
Given orally
vincristine sulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Collection of the clinical and laboratory data necessary for placing patients with acute lymphoblastic leukemia (ALL) onto the proper therapeutic trial (Classification)
- Creation of an administrative base to capture classification data for correlative studies in ALL treatment protocols and series of historical protocols (Classification)
- Creation of appropriate induction regimens for patients (Induction therapy)
- Correlation between event-free survival and measures of minimal-residual disease/early response
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.